Abstract
Cancer is a lethal disease, and its therapy should be tailed to individual patients by functional imaging to optimize therapy strategies. Single-photon emission computed tomography (SPECT) is a quantitative functional imaging modality used by oncologists to monitor tumor response. SPECT can track therapy-induced biological and metabolic changes in tumors; such changes usually precede anatomical alterations. Assessment of treatment response using SPECT tracers may result in modifications in treatment planning and predicting the long-term outcome. These SPECT tracers can be classified into metabolism, cell surface receptor, intracellular receptor, microenvironment, and apoptosis tracers. The most widely used SPECT tracers include 201Tl-thallium chloride, 67Ga-gallium citrate, 123I/131I-sodium iodide, 99mmTc-MIBI, 99mTc-MDP, and 123I/131I –MIBG. Apoptosis tracers, which can directly monitor early tumor response in cancer patients and can predict the outcome, have attracted increasing attention in the field of oncology. Annexin V-based SPECT tracers, including 99mTc-BTAP-annexin V, 99mTc-HYNIC-annexin-V, 99mTc-EC-annexin-V, 99mTc-i-annexin V, and 123I-annexin V, have been evaluated in clinical trials. Novel SPECT tracers, such as radiolabeled small molecules, aptamers, peptides, and proteins, need to be explored in the future to further improve the outcome of cancer therapy. In this review, SPECT tracers used to predict and monitor cancer therapy in both preclinical and clinical settings are summarized. Some tracers may contribute to the improvement of cancer therapy management.
Keywords: Cancer therapy, Evaluation, Prediction, SPECT, Tracer.
Current Pharmaceutical Biotechnology
Title:Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Volume: 14 Issue: 7
Author(s): Jiong Cai and Fang Li
Affiliation:
Keywords: Cancer therapy, Evaluation, Prediction, SPECT, Tracer.
Abstract: Cancer is a lethal disease, and its therapy should be tailed to individual patients by functional imaging to optimize therapy strategies. Single-photon emission computed tomography (SPECT) is a quantitative functional imaging modality used by oncologists to monitor tumor response. SPECT can track therapy-induced biological and metabolic changes in tumors; such changes usually precede anatomical alterations. Assessment of treatment response using SPECT tracers may result in modifications in treatment planning and predicting the long-term outcome. These SPECT tracers can be classified into metabolism, cell surface receptor, intracellular receptor, microenvironment, and apoptosis tracers. The most widely used SPECT tracers include 201Tl-thallium chloride, 67Ga-gallium citrate, 123I/131I-sodium iodide, 99mmTc-MIBI, 99mTc-MDP, and 123I/131I –MIBG. Apoptosis tracers, which can directly monitor early tumor response in cancer patients and can predict the outcome, have attracted increasing attention in the field of oncology. Annexin V-based SPECT tracers, including 99mTc-BTAP-annexin V, 99mTc-HYNIC-annexin-V, 99mTc-EC-annexin-V, 99mTc-i-annexin V, and 123I-annexin V, have been evaluated in clinical trials. Novel SPECT tracers, such as radiolabeled small molecules, aptamers, peptides, and proteins, need to be explored in the future to further improve the outcome of cancer therapy. In this review, SPECT tracers used to predict and monitor cancer therapy in both preclinical and clinical settings are summarized. Some tracers may contribute to the improvement of cancer therapy management.
Export Options
About this article
Cite this article as:
Cai Jiong and Li Fang, Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy, Current Pharmaceutical Biotechnology 2013; 14 (7) . https://dx.doi.org/10.2174/1389201014666131226105651
DOI https://dx.doi.org/10.2174/1389201014666131226105651 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Glance on the Role of Bacterial Siderophore from the Perspectives of Medical and Biotechnological Approaches
Current Drug Targets Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation
Current Drug Targets The Role of the Osteoimmune Axis in the Inflammation of the Inner Auditory Ear and with Regard to the Putative Anticarcinogenetic Principle: Part 2
Inflammation & Allergy - Drug Targets (Discontinued) Docking Studies for Multi-Target Drugs
Current Drug Targets Flavonoids in Neurodegeneration: Limitations and Strategies to Cross CNS Barriers
Current Medicinal Chemistry Pioglitazone, Bladder Cancer, and the Presumption of Innocence
Current Drug Safety Targeting Gene Therapy for Prostate Cancer
Current Pharmaceutical Design Polymeric Carriers for Gene Delivery: Chitosan and Poly(amidoamine) Dendrimers
Current Pharmaceutical Design Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing
Current Drug Delivery Atypical GTPases as Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Omega-3 Fatty Acid Treatment Combined with Chemotherapy to Prevent Toxicity, Drug Resistance, and Metastasis in Cancer
Current Drug Targets Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design Agaricus blazei Water Extracts as Alternative Medicines
Current Pharmaceutical Analysis The Mechanisms and Quantification of the Selective Permeability in Transport Across Biological Barriers: the Example of Kyotorphin
Mini-Reviews in Medicinal Chemistry In silico Methods for Designing Antagonists to Anti-apoptotic Members of Bcl-2 Family Proteins
Mini-Reviews in Medicinal Chemistry The Functions of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry Withdrawal Notice: Electrophoresis as a Tool for Early Cancer Diagnosis
Anti-Cancer Agents in Medicinal Chemistry